A clinical comparative study of two intubating doses of cis-atracurium during general anaesthesia for gynaecological surgery
| العنوان: | A clinical comparative study of two intubating doses of cis-atracurium during general anaesthesia for gynaecological surgery |
|---|---|
| المؤلفون: | Prakash Jammar, Ram Chandraji Chauhan, Deba Gopal Pathak, Ismatara Begum |
| المصدر: | International Journal of Basic & Clinical Pharmacology. 6:1206 |
| بيانات النشر: | Medip Academy, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, business.industry, Hemodynamics, Loading dose, Neuromuscular-blocking drug, Group B, Surgery, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Anesthesia, medicine, General anaesthesia, 030212 general & internal medicine, Hemodynamic stability, Adverse effect, business, Histamine |
| الوصف: | Background: Cisatracurium is one of the cis-cis isomer of atracurium (51W89:1R-cis 1’R-cis atracurium) an intermediate duration non-depolarising neuromuscular blocking drug and is devoid of histamine release. However, 2× ED95 dose of cisatracurium does not provide satisfactory intubating condition. The recommended intubating dose of cisatracurium is 3 ×ED95. The objective of this study was to evaluate and compare duration of action, hemodynamic effects and any adverse effects for different doses of cisatracurium.Methods: After Institutional Ethical Committee approval and informed patient consent, 80 patients of ASA I and II in the age group of 20-60 years were selected and included in the study. Patients were divided in two groups of 40 each, group A received intravenously 3×ED95 (0.15 mg/kg) loading dose of cisatracurium and group B received intravenously 4×ED95 (0.2 mg/kg) loading dose of cisatracurium.Results: After induction, MAP and HR shows decrease in both groups but neither statistically nor clinically significant. Better hemodynamic stability and longer duration of action was found in group B compared to group A. No adverse effects noted in both groups.Conclusions: 4×ED95 dose of cisatracurium provides longer duration of action and more stable hemodynamic status than 3×ED95. No associated signs of histamine release were detected clinically. |
| تدمد: | 2279-0780 2319-2003 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::490e424f984fa9d891fc18cb4dc24cfc https://doi.org/10.18203/2319-2003.ijbcp20171677 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........490e424f984fa9d891fc18cb4dc24cfc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22790780 23192003 |
|---|